HD-MAP Influenza Vaccine
Influenza Prevention
Phase 2/3Active
Key Facts
About Vaxxas
Vaxxas is a private, clinical-stage biotech founded in 2011, pioneering a needle-free vaccine delivery platform. Its core technology, the HD-MAP patch, uses thousands of micro-projections to deliver vaccine to the skin, aiming to improve immune response, enable thermostable formulations, and simplify administration. The company has validated its platform in human studies, secured significant partnerships with entities like Merck, BARDA, and CEPI, and is advancing a pipeline focused on influenza and other vaccines towards commercialization.
View full company profileTherapeutic Areas
Other Influenza Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA-based Broad Flu Vaccine | Micron Biomedical | Pre-clinical |
| CaPtivaX Nasal Influenza Vaccine | CaPtivate Pharmaceuticals | Pre-clinical |
| Next-Generation Influenza Vaccines | Fluart Innovative Vaccines | Not Disclosed |
| IRT Platform (e.g., Influenza) | Biological Mimetics | Research/Pre-clinical |